Skye Bioscience financials
$1.59−1.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$58.2M | -$30.2M |
| Net income | -$55.9M | -$26.6M |
| Net margin | — | — |
| Diluted EPS | $-11.28 | $-5.84 |
| EBITDA | -$57.4M | -$29.9M |
| Operating cash flow | -$43.1M | -$25.2M |
| Free cash flow | -$43.1M | -$26.8M |
| Diluted shares | 5.0M | 4.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $5.9M | $68.4M |
| Short-term investments | $19.9M | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $28.3M | $72.8M |
| Total liabilities | $8.3M | $4.6M |
| Shareholders' equity | $20.0M | $68.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology